Transaction details
Eugene Schneider, Ionis Pharmaceuticals' executive vice president and chief clinical development officer, reported the sale of 6,179 shares of common stock on January 30, 2026, for total proceeds of $515,629. According to a Form 4 filing with the Securities and Exchange Commission, the shares were sold in a price range from $83.32 to $83.48 per share, levels that sit near the company's 52-week high of $86.15.
Prior acquisition and holdings
The filing also shows Schneider acquired 11,991 Ionis shares on January 29, 2026. Those shares resulted from the vesting of performance-based restricted stock units and carried a reported price of $0.0. After completing these transactions, Schneider is recorded as directly holding 69,702 shares of Ionis common stock.
Share-price context
Ionis shares have experienced notable appreciation, climbing 158.5% over the last year and rising 93% in the prior six months. Despite the strong momentum in the share price, analysis provided through InvestingPro indicates the stock may appear expensive on certain valuation measures. The InvestingPro analysis highlights a high Price/Book ratio of 21.8 and notes that Ionis is not yet profitable.
Investors are informed that additional ProTips and a comprehensive Pro Research Report covering Ionis and more than 1,400 other U.S. equities are available through the InvestingPro service.
Recent clinical and regulatory developments
Ionis has registered several important advances on the clinical and regulatory fronts. The company received European Commission approval for Dawnzera, a therapy for hereditary angioedema, following successful Phase 3 clinical trials. In collaboration with GSK, Ionis reported positive Phase 3 results for bepirovirsen in chronic hepatitis B, including statistically significant functional cure rates. Separately, the Food and Drug Administration granted Breakthrough Therapy designation to Ionis' candidate zilganersen for Alexander disease after encouraging study results.
Analyst commentary and price targets
On the analyst front, RBC Capital upgraded its price target for Ionis to $95, citing the company's progression toward becoming a fully integrated commercial entity and pointing to the performance of Tryngolza in the familial chylomicronemia syndrome market and its potential role in severe hypertriglyceridemia. TD Cowen reiterated a Buy rating and set a $99 price target, identifying multiple growth drivers including Tryngolza, Dawnzera, and zilganersen.
Note on limits of available information: The filing and the subsequent analysis provide specific transaction details and contextual company developments. No further insider intent or future management actions are reported in the public filings referenced.